<p>哈德遜灣資本管理公司在最近向證券交易委員會提交的文件中表示，在第四季度將其在武田製藥有限公司（NYSE:TAK - 免費報告）的持股比例提高了 10.0%。該公司在季度內購買了額外的 25,000 股後，持有該公司 275,000 股股票。截至其最近向證券交易委員會提交的文件，哈德遜灣資本管理公司在武田製藥的持股價值為 3,641,000 美元。</p>
<p>獲取 <strong>武田製藥</strong> 的提醒：</p>
<ul>
<li>分析師預測 Wave Life Sciences 在降息後有 85% 的上漲空間</li>
</ul>
<p>其他一些機構投資者最近也買賣了該股票的股份。Farther Finance Advisors LLC 在第四季度將其在武田製藥的持股比例提高了 123.6%。Farther Finance Advisors LLC 現在擁有 3,575 股該公司的股票，價值 47,000 美元，在此期間又購買了 1,976 股。Crowley Wealth Management Inc.在第四季度獲得了武田製藥的新頭寸，價值約 52,000 美元。Cromwell Holdings LLC 在第四季度獲得了武田製藥的新頭寸，價值約 61,000 美元。Venturi Wealth Management LLC 在第四季度將其在武田製藥的持股比例提高了 554.7%。Venturi Wealth Management LLC 現在擁有 5,028 股該公司的股票，價值 67,000 美元，在上個季度又購買了 4,260 股。最後，Lindbrook Capital LLC 在第四季度將其在武田製藥的持股比例提高了 65.0%。Lindbrook Capital LLC 現在擁有 5,151 股該公司的股票，價值 68,000 美元，在此期間又購買了 2,029 股。對沖基金和其他機構投資者持有該公司 9.17% 的股票。</p>
<h2>武田製藥股價下跌 1.4%</h2>
<p>NYSE TAK 的股票在週二開盤價為 14.17 美元。該公司的流動比率為 1.31，速動比率為 0.72，債務與股本比率為 0.63。武田製藥有限公司的股價在一年內最低為 12.58 美元，最高為 15.43 美元。該公司的 50 日移動平均價格為 14.86 美元，200 日移動平均價格為 14.00 美元。該公司的市值為 450.7 億美元，市盈率為 35.41，市盈增長比率為 0.24，貝塔值為 0.26。</p>
<ul>
<li>現在是購買這三家提高收入指引的醫療公司嗎？</li>
</ul>
<p>武田製藥（NYSE:TAK - 獲取免費報告）最近在 5 月 8 日星期四發佈了季度財報。該公司報告季度每股收益為 0.16 美元，低於市場共識預期的 0.24 美元，差距為 0.08 美元。武田製藥的股本回報率為 9.39%，淨利潤率為 4.53%。該公司季度收入為 73.4 億美元，而分析師預期為 80.2 億美元。整體來看，分析師預測武田製藥有限公司在當前財政年度的每股收益為 1.64 美元。</p>
<h2>華爾街分析師的看法</h2>
<p>另外，摩根士丹利在 4 月 2 日星期三的一份研究報告中將武田製藥的評級從 “持平” 上調至 “增持”。</p>
<ul>
<li>價格增長與收益：為了那種神奇的組合，離開美國。</li>
</ul>
<p><strong>查看我們關於武田製藥的最新股票報告</strong></p>
<h2>武田製藥公司簡介</h2>
<p>（免費報告）</p>
<p>武田製藥有限公司從事藥品的研究、開發、生產、營銷和外部授權，業務遍及日本及國際市場。它在胃腸病、罕見疾病、血漿衍生療法、免疫學、腫瘤學和神經科學等領域提供藥品。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票超過武田製藥</li>
<li>每月分紅股票的利弊</li>
<li>Palantir 的最新交易可能會凍結其股價</li>
<li>交易股票：相對強弱指數及其用途</li>
<li>4 家汽車製造商股票對關税的反應：贏家與輸家</li>
<li>投資者必須瞭解的場外交易（OTC）股票</li>
<li>這就是為什麼期權交易者喜歡 Dutch Bros 股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRBSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRBSw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在武田製藥嗎？</h2>
<p>在你考慮武田製藥之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而武田製藥並不在名單上。</p>
<p>雖然武田製藥目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

4502

<p>根據 Hudson Bay Capital Management LP 最近向證券交易委員會提交的文件，該公司在第四季度將其在武田藥品工業株式會社（NYSE:TAK - 免費報告）的持股比例提高了 10.0%</p>

<p>Hudson Bay Capital Management LP lifted its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 10.0% in the fourth quarter, according to its most recent filing with the Securities &amp; Exchange Commission. The firm owned 275,000 shares of the company's stock after purchasing an additional 25,000 shares during the quarter. Hudson Bay Capital Management LP's holdings in Takeda Pharmaceutical were worth $3,641,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p>
<div class="lb-trans"><p>哈德遜灣資本管理公司在最近向證券交易委員會提交的文件中表示，在第四季度將其在武田製藥有限公司（NYSE:TAK - 免費報告）的持股比例提高了 10.0%。該公司在季度內購買了額外的 25,000 股後，持有該公司 275,000 股股票。截至其最近向證券交易委員會提交的文件，哈德遜灣資本管理公司在武田製藥的持股價值為 3,641,000 美元。</p>
</div><p>Get <strong>Takeda Pharmaceutical</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>武田製藥</strong> 的提醒：</p>
</div><ul>
<li>Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut</li>
</ul>
<div class="lb-trans"><ul>
<li>分析師預測 Wave Life Sciences 在降息後有 85% 的上漲空間</li>
</ul>
</div><p>A number of other institutional investors have also recently bought and sold shares of the stock. Farther Finance Advisors LLC boosted its holdings in shares of Takeda Pharmaceutical by 123.6% in the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock worth $47,000 after buying an additional 1,976 shares during the period. Crowley Wealth Management Inc. acquired a new position in Takeda Pharmaceutical in the 4th quarter worth approximately $52,000. Cromwell Holdings LLC acquired a new position in Takeda Pharmaceutical in the 4th quarter worth approximately $61,000. Venturi Wealth Management LLC grew its position in Takeda Pharmaceutical by 554.7% during the 4th quarter. Venturi Wealth Management LLC now owns 5,028 shares of the company's stock worth $67,000 after purchasing an additional 4,260 shares in the last quarter. Finally, Lindbrook Capital LLC raised its stake in Takeda Pharmaceutical by 65.0% during the 4th quarter. Lindbrook Capital LLC now owns 5,151 shares of the company's stock valued at $68,000 after purchasing an additional 2,029 shares during the period. Hedge funds and other institutional investors own 9.17% of the company's stock.</p>
<div class="lb-trans"><p>其他一些機構投資者最近也買賣了該股票的股份。Farther Finance Advisors LLC 在第四季度將其在武田製藥的持股比例提高了 123.6%。Farther Finance Advisors LLC 現在擁有 3,575 股該公司的股票，價值 47,000 美元，在此期間又購買了 1,976 股。Crowley Wealth Management Inc.在第四季度獲得了武田製藥的新頭寸，價值約 52,000 美元。Cromwell Holdings LLC 在第四季度獲得了武田製藥的新頭寸，價值約 61,000 美元。Venturi Wealth Management LLC 在第四季度將其在武田製藥的持股比例提高了 554.7%。Venturi Wealth Management LLC 現在擁有 5,028 股該公司的股票，價值 67,000 美元，在上個季度又購買了 4,260 股。最後，Lindbrook Capital LLC 在第四季度將其在武田製藥的持股比例提高了 65.0%。Lindbrook Capital LLC 現在擁有 5,151 股該公司的股票，價值 68,000 美元，在此期間又購買了 2,029 股。對沖基金和其他機構投資者持有該公司 9.17% 的股票。</p>
</div><h2>Takeda Pharmaceutical Trading Down 1.4%</h2>
<div class="lb-trans"><h2>武田製藥股價下跌 1.4%</h2>
</div><p>Shares of NYSE TAK opened at $14.17 on Tuesday. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. Takeda Pharmaceutical Company Limited has a one year low of $12.58 and a one year high of $15.43. The business has a 50-day moving average price of $14.86 and a two-hundred day moving average price of $14.00. The firm has a market capitalization of $45.07 billion, a PE ratio of 35.41, a PEG ratio of 0.24 and a beta of 0.26.</p>
<div class="lb-trans"><p>NYSE TAK 的股票在週二開盤價為 14.17 美元。該公司的流動比率為 1.31，速動比率為 0.72，債務與股本比率為 0.63。武田製藥有限公司的股價在一年內最低為 12.58 美元，最高為 15.43 美元。該公司的 50 日移動平均價格為 14.86 美元，200 日移動平均價格為 14.00 美元。該公司的市值為 450.7 億美元，市盈率為 35.41，市盈增長比率為 0.24，貝塔值為 0.26。</p>
</div><ul>
<li>Time to buy these 3 healthcare companies that raised revenue guidance?</li>
</ul>
<div class="lb-trans"><ul>
<li>現在是購買這三家提高收入指引的醫療公司嗎？</li>
</ul>
</div><p>Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.24 by ($0.08). Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. The company had revenue of $7.34 billion for the quarter, compared to analyst estimates of $8.02 billion. As a group, analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>武田製藥（NYSE:TAK - 獲取免費報告）最近在 5 月 8 日星期四發佈了季度財報。該公司報告季度每股收益為 0.16 美元，低於市場共識預期的 0.24 美元，差距為 0.08 美元。武田製藥的股本回報率為 9.39%，淨利潤率為 4.53%。該公司季度收入為 73.4 億美元，而分析師預期為 80.2 億美元。整體來看，分析師預測武田製藥有限公司在當前財政年度的每股收益為 1.64 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師的看法</h2>
</div><p>Separately, Morgan Stanley raised Takeda Pharmaceutical from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating in a research report on Wednesday, April 2nd.</p>
<div class="lb-trans"><p>另外，摩根士丹利在 4 月 2 日星期三的一份研究報告中將武田製藥的評級從 “持平” 上調至 “增持”。</p>
</div><ul>
<li>Price Growth &amp; Yield: For That Magical Combo, Leave the U.S.</li>
</ul>
<div class="lb-trans"><ul>
<li>價格增長與收益：為了那種神奇的組合，離開美國。</li>
</ul>
</div><p><strong>View Our Latest Stock Report on Takeda Pharmaceutical</strong></p>
<div class="lb-trans"><p><strong>查看我們關於武田製藥的最新股票報告</strong></p>
</div><h2>Takeda Pharmaceutical Company Profile</h2>
<div class="lb-trans"><h2>武田製藥公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.</p>
<div class="lb-trans"><p>武田製藥有限公司從事藥品的研究、開發、生產、營銷和外部授權，業務遍及日本及國際市場。它在胃腸病、罕見疾病、血漿衍生療法、免疫學、腫瘤學和神經科學等領域提供藥品。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Takeda Pharmaceutical</li>
<li>Pros And Cons Of Monthly Dividend Stocks</li>
<li>Palantir’s Latest Deal Could Put a Freeze on Its Stock Price</li>
<li>Trading Stocks: RSI and Why it's Useful</li>
<li>4 Automaker Stocks React to Tariffs: Winners and Losers</li>
<li>What Investors Must Know About Over-the-Counter (OTC) Stocks</li>
<li>Here's Why Call Option Traders Love Dutch Bros Stock</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過武田製藥</li>
<li>每月分紅股票的利弊</li>
<li>Palantir 的最新交易可能會凍結其股價</li>
<li>交易股票：相對強弱指數及其用途</li>
<li>4 家汽車製造商股票對關税的反應：贏家與輸家</li>
<li>投資者必須瞭解的場外交易（OTC）股票</li>
<li>這就是為什麼期權交易者喜歡 Dutch Bros 股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRBSw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=TAK"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Takeda Pharmaceutical Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在武田製藥嗎？</h2>
</div><p>Before you consider Takeda Pharmaceutical, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮武田製藥之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而武田製藥並不在名單上。</p>
</div><p>While Takeda Pharmaceutical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然武田製藥目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Hudson Bay Capital Management LP 增加了對武田藥品工業株式會社（NYSE:TAK）的持股